TSE Investors Have Opportunity to Join Trinseo PLC Fraud Investigation with the Schall Law Firm
LOS ANGELES–(BUSINESS WIRE)–$TSE—The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims... Read more.
Jefferies Provides Letter from Its CEO and President Regarding Point Bonita Capital and First Brands Group
NEW YORK–(BUSINESS WIRE)–Jefferies Financial Group, Inc. (NYSE: JEF) (“Jefferies”) announced today that is has posted this letter from our CEO, Rich... Read more.
PLTR Investors Have Opportunity to Join Palantir Technologies Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES–(BUSINESS WIRE)–$PLTR—The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims... Read more.
Trinseo PLC Investigated for Securities Fraud Violations – Contact the DJS Law Group to Discuss Your Rights – TSE
LOS ANGELES–(BUSINESS WIRE)–The DJS Law Group announces that it is investigating claims on behalf of investors of Trinseo PLC (“Trinseo” or “the... Read more.
Palantir Technologies Inc. Investigated for Securities Fraud Violations – Contact the DJS Law Group to Discuss Your Rights – PLTR
LOS ANGELES–(BUSINESS WIRE)–The DJS Law Group announces that it is investigating claims on behalf of investors of Palantir Technologies Inc. (“Palantir”... Read more.
New Report by CAPS: Asian Philanthropy Positioned to Lead on Maternal and Child Health as Foreign Aid Retreats
The Centre for Asian Philanthropy and Society research examines unique approaches by domestic funders in China, India, Indonesia, and the Philippines as the landscape... Read more.
AdvanCell to Present Promising Clinical Trial Results of ADVC001, a Novel Lead-212-based PSMA-targeted Alpha Therapy for Prostate Cancer, at ESMO 2025
Results from the Phase 1b dose escalation of the TheraPb Phase 1/2 trial are the first clinical data for a Lead-212 (212Pb)-based-PSMA radioligand therapy The abstract... Read more.
Natera to Present 14 Studies at ESMO, Including IMvigor011 Oral Presentation in Presidential Symposium
Six oral presentations highlight Signatera’s expanding role across solid tumors, including definitive predictive data in adjuvant bladder cancer AUSTIN, Texas–(BUSINESS... Read more.
Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatment of Unresectable or Advanced Gastroesophageal Adenocarcinomas in the Phase 2 EDGE-Gastric Study
First overall survival (OS) results from Arm A1 of the Phase 2 EDGE-Gastric study will be presented on October 18 at the European Society for Medical Oncology (ESMO)... Read more.
Data from Incyte’s TGFβR2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology (ESMO) Congress 2025
WILMINGTON, Del.–(BUSINESS WIRE)–$INCY #ESMO2025–Incyte (Nasdaq:INCY) today announced that results from Phase 1 proof-of-concept studies of INCA33890,... Read more.